Patent Assignment
Reel/Frame 039266/0345
Security Interest
Recorded: 2016-07-06
Pages: 13
Assignee
DEUTSCHE BANK AG NEW YORK BRANCH
5022 GATE PARKWAY, SUITE 100, JACKSONVILLE, FLORIDA, 32256
Covered Properties
(104)
Localized Use of Nitric Oxide-Adducts to Prevent Internal Tissue Damage
Patent:
6,087,479 →
Application:
08/460,465 →
Methods of Treating and Preventing Congestive Heart Failure with Hydralazine Compounds and Isosorbide Dinitrate or Isosorbide Mononitrate
Patent:
6,465,463 →
Application:
09/658,261 →
Methods of Treating Vascular Diseases Characterized by Nitric Oxide Insufficiency
Patent:
6,635,273 →
Application:
09/697,317 →
Methods for Synthesis of Prodrugs from 1-Acyl-Alkyl Derivatives and Compositions Thereof
Orally Administered Dosage Forms of Gaba Analog Prodrugs Having Reduced Toxicity
Prodrugs of Gaba Analogs, Compositions and Uses Thereof
Methods of Treating and Preventing Congestive Heart Failure with Hydralazine Compounds and Isosorbide Dinitrate or Isosorbide Mononitrate
Prodrugs of Gaba Analogs, Compositions and Uses Thereof
Methods for Synthesis of Acyloxyalkyl Derivatives of Gaba Analogs
A Transdermal Patch Composition for Treating Vascular Diseases Characterized by Nitric Oxide Insufficiency
Composition For Treating Vascular Diseases Characterized By Nitric Oxide Insufficiency
Amino Acid Derived Prodrugs of Propofol, Compositions and Uses Thereof
Methods for Synthesis of Acyloxyalkyl Compounds
Acyloxyalkyl Carbamate Prodrugs, Methods of Synthesis and Use
Treating Urinary Incontinence Using Prodrugs of Gaba Analogs
Crystalline Form of Y-Aminobutyric Acid Analog
Treating or Preventing Restless Legs Syndrome Using Prodrugs of Gaba Analogs
Synthesis of Acyloxyalkyl Carbamate Prodrugs and Intermediates Thereof
Prodrugs of Gaba Analogs, Compositions and Uses Thereof
Levodopa Prodrugs, and Compositions and Uses Thereof
Levodopa Prodrugs, and Compositions and Uses Thereof
Methods for Synthesis of Prodrugs from 1-Acyl-Alkyl Derivatives and Compositions Thereof
Amino Acid Derived Prodrugs of Propofol, Compositions and Uses Thereof
Gaba Analog Prodrug Sustained Release Oral Dosage Forms
Amino Acid Derived Prodrugs of Propofol, Compositions, Uses and Crystalline Forms Thereof
Platinum-Containing Compounds Exhibiting Cytostatic Activity, Synthesis and Methods of Use
Prodrugs of Gaba Analogs, Compositions and Uses Thereof
Aromatic Prodrugs of Propofol, Compositions and Uses Thereof
Acyloxyalkyl Carbamate Prodrugs, Methods of Synthesis and Use
Methods for Synthesis of Acyloxyalkyl Derivatives of Gaba Analogs
Levodopa Prodrug Mesylate, Compositions Thereof, and Uses Thereof
Synthesis of Acyloxyalkyl Carbamate Prodrugs and Intermediates Thereof
Gemcitabine Prodrugs, Pharmaceutical Compositions and Uses Thereof
Topical Avermectin Formulations and Methods for Elimination and Prophylaxis of Susceptible and Treatment-Resistant Strains of Head Lice
Acyloxyalkyl Carbamate Prodrugs, Methods of Synthesis and Use
Sustained Release Oral Dosage Forms of a Prodrug of R-Baclofen and Methods of Treatment
Application:
11/972,575 →
Publication:
US 2008/0206332
Levodopa Prodrugs, and Compositions and Uses Thereof
Levodopa Prodrugs, and Compositions and Uses Thereof
Levodopa Prodrug Mesylate, Compositions Thereof, and Uses Thereof
Crystalline Form of a (3S)-Aminomethyl-5-Methyl-Hexanoic Acid Prodrug and Methods of Use
Mesophasic Forms of (3S)-Aminomethyl-5-Methyl-Hexanoic Acid Prodrugs and Methods of Use
Enantiomerically Resolving Acyloxyalkyl Thiocarbonates Used in Synthesizing Acyloxyalkyl Carbamate Prodrugs
Levodopa Prodrugs, and Compositions and Uses Thereof
Synthesis of Acyloxyalkyl Carbamate Prodrugs and Intermediates Thereof
Methods for Synthesis of Prodrugs from 1-Acyl-Alkyl Derivatives and Compositions Thereof
Levodopa Prodrug Mesylate, Compositions Thereof, and Uses Thereof
Methods of Synthesizing N-Hydroxysuccinimidyl Carbonates
Methods of Synthesizing 1-(Acyloxy)-Alkyl Carbamate Prodrugs
Methods for Synthesis of Acyloxyalkyl Compounds
Prodrugs of Methyl Hydrogen Fumarate, Pharmaceutical Compositions Thereof, and Methods of Use
Methods of Synthesizing a Levodopa Ester Prodrug
Levodopa Prodrug Mesylate Hydrate
Sustained Release Oral Dosage Forms of an R-Baclofen Prodrug
Oral Dosage Forms Having a High Loading of a Gabapentin Prodrug
Application:
12/718,857 →
Publication:
US 2010/0226981
Prodrugs of Gaba Analogs, Compositions and Uses Thereof
Acyloxyalkyl Carbamate Prodrugs, Methods of Synthesis and Use
Application:
12/883,860 →
Publication:
US 2011/0021571
Pharmaceutical Compositions and Oral Dosage Forms of a Levodopa Prodrug and Methods of Use
Crystalline Form of a (3S)-Aminomethyl-5-Methyl-Hexanoic Acid Prodrug and Methods of Use
Levodopa Prodrug Mesylate, Compositions Thereof, and Uses Thereof
Use of (3R)-4-{[(1S)-2-Methyl-1-(2-Methylpropanoyloxy)Propoxy]Carbonylamino}-3-(4-Chlorophenyl) Butanoic Acid for Treating Urinary Incontinence
Levodopa Prodrugs, and Compositions and Uses Thereof
Topical Avermectin Formulations and Methods for Elimination and Prophylaxis of Susceptible and Treatment Resistant Strains of Head Lice
CRYSTALLINE FORM OF y-AMINOBUTYRIC ACID ANALOG
Methods of Treating Fragile X Syndrome, Down's Syndrome, Autism and Related Disorders
Application:
13/184,070 →
Publication:
US 2012/0016021
Synthesis of Acyloxyalkyl Carbamate Prodrugs and Intermediates Thereof
Methods of Using Prodrugs of Pregabalin
Prodrugs of Methyl Hydrogen Fumarate, Pharmaceutical Compositions Thereof, and Methods of Use
Methods of Using Prodrugs of Methyl Hydrogen Fumarate and Pharmaceutical Compositions Thereof
Anhydrous and Hemihydrate Crystalline Forms of an (R)-Baclofen Prodrug, Methods of Synthesis and Methods of Use
Prodrugs of Gaba Analogs, Compositions and Uses Thereof
Application:
13/714,224 →
Publication:
US 2013/0102641
Synthesis of Acyloxyalkyl Carbamate Prodrugs and Intermediates Thereof
Morpholinoalkyl Fumarate Compounds, Pharmaceutical Compositions, and Methods of Use
Levodopa Prodrug Mesylate Hydrate
Treatment of Multiple Sclerosis and Psoriasis Using Prodrugs of Methyl Hydrogen Fumarate
Application:
13/906,155 →
Publication:
US 2013/0324539
Morpholinoalkyl Fumarate Compounds, Pharmaceutical Compositions, and Methods of Use
Application:
13/967,283 →
Publication:
US 2014/0051705
Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof
Oral Dosage Forms Having a High Loading of a Methyl Hydrogen Fumarate Prodrug
Application:
13/973,542 →
Publication:
US 2014/0056973
Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof
Application:
13/973,622 →
Publication:
US 2014/0056978
Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects
Methods of Administering Monomethyl Fumarate
Application:
13/973,780 →
Publication:
US 2014/0275250
Methods of Use for Monomethyl Fumarate and Prodrugs Thereof
Application:
13/973,820 →
Publication:
US 2014/0057918
Anhydrous and Hemihydrate Crystalline Forms of an (R)-Baclofen Prodrug, Methods of Synthesis and Methods of Use
Method of Making 1-(Acyloxy)-Alkyl Carbamate Compounds
Application:
14/189,555 →
Publication:
US 2014/0243544
CRYSTALLINE FORM OF y-AMINOBUTYRIC ACID ANALOG
Pharmaceutical Compositions of Dimethyl Fumarate
Sotalol Compositions and Uses of the Same
Methods of Using Prodrugs of Methyl Hydrogen Fumarate and Pharmaceutical Compositions Thereof
Method of Making Monomethyl Fumarate
Gaba Analog Prodrug Sustained Release Oral Dosage Forms
Cocrystals of Dimethyl Fumarate
Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects
Application:
14/449,513 →
Publication:
US 2015/0038499
Crystalline Forms of (N,N-Diethylcarbamoyl)Methyl Methyl (2E)but-2-Ene-1,4-Dioate, Methods of Synthesis and Use
Nanoparticle Compositions of Dimethyl Fumarate
Application:
14/490,277 →
Publication:
US 2015/0079180
Gaba Analog Prodrug Sustained Release Oral Dosage Forms
Application:
14/532,854 →
Publication:
US 2015/0072004
Topical Avermectin Formulations and Methods for Elimination and Prophylaxis of Susceptible and Treatment Resistant Strains of Head Lice
Application:
14/572,664 →
Publication:
US 2015/0105340
Methods of Administering Monomethyl Fumarate
Application:
14/661,698 →
Publication:
US 2015/0190360
Pharmaceutical Compositions of Fumaric Acid Esters
Treatment of Multiple Sclerosis and Psoriasis Using Prodrugs of Methyl Hydrogen Fumarate
Application:
14/717,639 →
Publication:
US 2015/0252013
Prodrugs of Gaba Analogs, Compositions and Uses Thereof
Anhydrous and Hemihydrate Crystalline Forms of an (R)-Baclofen Prodrug, Methods of Synthesis and Methods of Use
CRYSTALLINE FORM OF y-AMINOBUTYRIC ACID ANALOG
Application:
14/831,688 →
Publication:
US 2015/0353483
Prodrugs of Gaba Analogs, Compositions and Uses Thereof
Application:
14/962,715 →
Publication:
US 2016/0090353
Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof
Methods of Synthesizing a Levodopa Ester Prodrug
Related Assignments
(10)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
May 2, 2014
From: NITROMED, INC.
To: ARBOR PHARMACEUTICALS, LLC
Reel/Frame 032807/0096 →
Assignment of Assignor's Interest
Jun 4, 2015
From: GALLOP, MARK A.; CUNDY, KENNETH C.; ZHOU, CINDY X.; YAO, FENMEI
To: XENOPORT, INC.
Reel/Frame 035788/0560 →
Assignment of Intellectual Property Security Agreement
Nov 15, 2015
From: GENERAL ELECTRIC CAPITAL CORPORATION, AS RETIRING AGENT
To: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS SUCCESSOR AGENT
Reel/Frame 037112/0069 →
Assignment of Assignor's Interest
Apr 20, 2018
From: ARBOR PHARMACEUTICALS, LLC
To: XENOPORT, INC.
Reel/Frame 046449/0306 →
Assignment of Assignor's Interest
Jul 25, 2018
From: XENOPORT, INC.
To: ARBOR PHARMACEUTICALS, LLC
Reel/Frame 046633/0753 →
Release of Security Interest
Aug 11, 2021
From: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS SUCCESSOR AGENT
To: ARBOR PHARMACEUTICALS, LLC
Reel/Frame 057142/0980 →
Security Interest
Sep 20, 2021
From: ARBOR PHARMACEUTICALS, LLC
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 057544/0803 →
Release of Security Interest
Oct 20, 2021
From: DEUTSCHE BANK AG NEW YORK BRANCH
To: ARBOR PHARMACEUTICALS, LLC; WILSHIRE PHARMACEUTICALS, INC.; XENOPORT, INC.
Reel/Frame 057880/0174 →
Release of Security Interest
Mar 14, 2025
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: AZURITY PHARMACEUTICALS, INC.; SILVERGATE PHARMACEUTICALS, INC.; ARBOR PHARMACEUTICALS, LLC; SLAYBACK PHARMA LIMITED LIABILITY COMPANY
Reel/Frame 070521/0299 →
Confirmatory Grant of Security Interest in United States Patents
Mar 17, 2025
From: ARBOR PHARMACEUTICALS, LLC; AZURITY PHARMACEUTICALS, INC.; AZURITY PHARMACEUTICALS IRELAND LIMITED; SILVERGATE PHARMACEUTICALS, INC.
To: HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 070531/0487 →